Clinton H. Severson

ABAXIS, Inc. engages in the development, manufacture, and marketing of portable blood analysis systems. It operates through the following segments: Medical Market, Veterinary Market, and Other. The Medical Market segment serves a customer group consisting of physicians’ office practices across multiple specialties, urgent care, outpatient and walk-in clinics, health screening operations, home care providers, nursing homes, ambulance companies, oncology treatment clinics, dialysis centers, pharmacies, hospital laboratories, military installations, pharmaceutical clinical trials, and cruise ship lines. The Veterinary Market segment focuses on animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies, and private research laboratories. The company was founded by Vladimir E. Ostoich in April 1989 and is headquartered in Union City, CA.

CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL.

Part of Johnson & Johnson, LXN Corp is a private company that develops and commercializes fructosamine monitoring technology for diabetes. The company is based in San Diego, CA. The company was founded by John F. Burd. LXN was acquired by Inverness Medical Technology, Inc. on March 29, 2001 for $18.48 million.

Response Biomedical Corp. engages in the research, development, commercialization, and distribution of diagnostic technologies. The firm serves the medical central-lab testing, point of care testing, and on-site environmental testing markets. It provides RAMP system, which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company was founded on August 20, 1980 and is headquartered in Vancouver, Canada.

IntelliDx, Inc. develops medical devices. It offers automated ex vivo blood analysis systems that measure the constituents of flowing human blood, and automated blood glucose monitoring systems that measure glucose in hospitalized patients who have abnormally elevated sugar levels. The company was founded in 2000 and is headquartered in Santa Clara, CA.

Bioxiness Pharmaceuticals, Inc. develops, manufactures and supplies pharmaceutical products. The company was founded by Mansour Bassiri in 2007 and is headquartered in Hercules, CA.

Part of Resonac Holdings Corp., MAST Immunosystems, Inc. is a private company that specializes in providing quality allergy care through their comprehensive panel test for environmental and food allergens called OPTIGEN® Allergen-Specific IgE Assay. The company is based in Mountain View, CA. The company also offers the OPTIGEN® Multiplex Allergen-Specific IgE Assay and the AP3600™ Fully-Automated System for OPTIGEN Allergy. MAST Immunosystems was acquired by Resonac Corp., part of Resonac Holdings Corp. from April 20, 2020 on November 04, 1996 for $40 million.